Literature DB >> 26850004

Syntheses and biological evaluation of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib.

Yong-Tao Li1, Jing-Han Wang1, Cheng-Wen Pan1, Fan-Fei Meng1, Xiao-Qian Chu2, Ya-hui Ding3, Wen-Zheng Qu1, Hui-ying Li2, Cheng Yang1, Quan Zhang3, Cui-Gai Bai4, Yue Chen5.   

Abstract

Three novel series of 1,2,3-triazole and 1,3,4-oxadiazole derivatives of imatinib were prepared and evaluated in vitro for their cytostatic effects against a human chronic myeloid leukemia (K562), acute myeloid leukemia (HL60), and human leukemia stem-like cell line (KG1a). The structure-activity relationship was analyzed by determining the inhibitory rate of each imatinib analog. Benzene and piperazine rings were necessary groups in these compounds for maintaining inhibitory activities against the K562 and HL60 cell lines. Introducing a trifluoromethyl group significantly enhanced the potency of the compounds against these two cell lines. Surprisingly, some compounds showed significant inhibitory activities against KG1a cells without inhibiting common leukemia cell lines (K562 and HL60). These findings suggest that these compounds are able to inhibit leukemia stem-like cells.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic myelogenous leukemia; Imatinib; K562; KG-1a; Synthesis

Mesh:

Substances:

Year:  2016        PMID: 26850004     DOI: 10.1016/j.bmcl.2016.01.068

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents.

Authors:  M Shaheer Malik; Saleh A Ahmed; Ismail I Althagafi; Mohammed Azam Ansari; Ahmed Kamal
Journal:  RSC Med Chem       Date:  2020-01-29

2.  A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model.

Authors:  Charles Samuel Umbaugh; Adriana Diaz-Quiñones; Manoel Figueiredo Neto; Joseph J Shearer; Marxa L Figueiredo
Journal:  Oncotarget       Date:  2017-12-13

3.  New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells.

Authors:  Andressa Oliveira; Stefany Moura; Luiz Pimentel; João Neto; Rafael Dantas; Floriano Silva-Jr; Monica Bastos; Nubia Boechat
Journal:  Molecules       Date:  2022-01-24       Impact factor: 4.411

4.  Tyrosol Derivatives, Bearing 3,5-Disubstituted Isoxazole and 1,4-Disubstituted Triazole, as Potential Antileukemia Agents by Promoting Apoptosis.

Authors:  Zaineb Abdelkafi-Koubaa; Imen Aissa; Hichem Ben Jannet; Najet Srairi-Abid; Naziha Marrakchi; Samia Menif
Journal:  Molecules       Date:  2022-08-10       Impact factor: 4.927

5.  Synthesis, Anticancer Activity and Molecular Docking Studies of Novel N-Mannich Bases of 1,3,4-Oxadiazole Based on 4,6-Dimethylpyridine Scaffold.

Authors:  Małgorzata Strzelecka; Teresa Glomb; Małgorzata Drąg-Zalesińska; Julita Kulbacka; Anna Szewczyk; Jolanta Saczko; Paulina Kasperkiewicz-Wasilewska; Nina Rembiałkowska; Kamil Wojtkowiak; Aneta Jezierska; Piotr Świątek
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

6.  Hybrids of Imatinib with Quinoline: Synthesis, Antimyeloproliferative Activity Evaluation, and Molecular Docking.

Authors:  Carine Santos; Luiz Pimentel; Henayle Canzian; Andressa Oliveira; Floriano Junior; Rafael Dantas; Lucas Hoelz; Debora Marinho; Anna Cunha; Monica Bastos; Nubia Boechat
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03

7.  Synthesis and characterisation of (Z)-styrylbenzene derivatives as potential selective anticancer agents.

Authors:  Ya-Bing Xin; Jia-Jun Li; Hong-Jian Zhang; Jun Ma; Xin Liu; Guo-Hua Gong; Yu-Shun Tian
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 8.  Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds.

Authors:  Alessandra Benassi; Filippo Doria; Valentina Pirota
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.